NICE recommendation of Forxiga (dapagliflozin), Invokana (canagliflozin) and Jardiance (empagliflozin) as monotherapies for type 2 diabetes
The National Institute for Health and Care Excellence (NICE) has, in draft guidance, recommended Forxiga (dapagliflozin) from AstraZeneca, Invokana (canagliflozin) from Janssen, and Jardiance (empagliflozin) from Eli Lilly + Boehringer, as monotherapies to treat type 2 diabetes in adults where diet and exercise do not provide adequate glycaemic control in patients for whom metformin is contraindicated or not tolerated. The recommendation applies if other classes of antidiabetic drugs, including DPP-4 inhibitors, would not otherwise be prescribed, and a sulfonylurea or pioglitazone is not appropiate.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins